Tectonic Therapeutic, Inc.

NASDAQ:TECX

Biotechnology

Healthcare
$21.04 -0.96%

-$0.29 today

Market cap
$411.32M
Beta
1.22
P/E (TTM)
-6.7
EPS (TTM)
-$4.45
52W Low $14.39High $36.03

Volume 0.17M

Average 0.20M

TECX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Tectonic Therapeutic, Inc.NASDAQ: TECX

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $847K fell 99.5% year over year, ahead of the -101.1% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +771.4% a year.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -99.5% holds above the trailing-twelve-month pace of -101.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$847K+700.7% QoQ
Last fiscal yearDec 2025
$173.36M+1.0% YoY
LTMMar 2026
-$3.92M-101.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.5%——
1 year+1.0%——
3-year CAGR+771.4%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
173.36M USD
Year-over-year change
+1.0%
4-year CAGR
+43.0%

Financing Cash Flow vs competitors

How TECX compares with its peers on the latest reported figures

  • TECX's LTM Mar 2026 financing cash flow of $3.92M is the smallest of the 4 companies compared; the peer median is $80.93M.
  • Its year-over-year change of -101.1% is the lowest of 4, against a peer median of -69.3%.
  • Over three fiscal years its annual growth of +771.4% compares with a peer median of +67.8%.
TECX Competitors Peer median
Financing Cash Flow for TECX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$759.79M +64071.1%+197.3%—
SEPNSepterna, Inc.LTM Sep 2026$80.93M -73.5%-61.7%84.1%
GENBGenerate Biomedicines, Inc.FY2025$28.06M -69.3%—88.0%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$3.92M -101.1%+771.4%—
Peer median (excluding TECX) $80.93M-69.3%+67.8%86.0%

Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.93M)(32.18K)(42.82M)(57.98M)(74.15M)
Depreciation & Amortization364K1.01K1.48M1.65M1.38M
Deferred Income Tax00000
Stock-Based Compensation639K1.12K1.12M3.49M10.5M
Change in Working Capital1.92M(7.4M)(584K)(10.28M)(70K)
Accounts Receivables00000
Inventory00000
Accounts Payables1.45M(3.1M)(165K)(1.42M)116K
Other Working Capital464K(4.3M)(419K)(8.86M)(186K)
Other Non-Cash Items(6.45M)(89.78M)127K4.04M2.27M
Operating Cash Flow(12.45M)(97.21M)(40.68M)(59.08M)(60.08M)
Capital Expenditures(2.12M)(267K)(279K)(156K)(208K)
Acquisitions (Net)000070K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(2.12M)(267K)(279K)(156K)(138K)
Debt Repayment3.61M(393K)(499K)(475K)(489K)
Common Stock Issued2K262K34.13M94.6M174.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0393K121K77.59M(485K)
Financing Cash Flow41.42M262K33.75M171.71M173.36M
Effect of Forex Changes0492K16K(8K)(95K)
Net Change in Cash26.84M(96.72M)(7.2M)112.47M113.04M
Free Cash Flow(14.58M)(97.48M)(40.96M)(59.24M)(60.29M)

Tectonic Therapeutic, Inc.

NASDAQ:TECX

Intrinsic Alpha fair value

Locked

Current Price

$21.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.